GLAXOSMITHKLINE PLC Form 6-K January 11, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 11 January 2019

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc(the'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')	
 Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley 	
b) Position/status Chief Executive Officer	
c) Initial notification/amendment Initial notification	
2. Details of the issuer, emission allowance market participant, auctio	n
platform, auctioneer or auction monitor	
a) Name GlaxoSmithKline plc	
b) LEI 5493000HZTVUYLO1D	
Details of the transaction(s): section to be repeated for (i) each type	
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each where transaction(s) has been conducted	ch place
Ordinary shares of 25 per	nce each
('Ordinary Shares')	
a) Description of the financial instrument	
ISIN: GB0009252882	
Acquisition of Ordinary S	
b) Nature of the transaction under the Company's Sha	re
Reward Plan.	
Price(s) Volume(s)	
c) Price(s) and volume(s) £15.2440 8 (partnership	shares)
£15.2440 8 (matching sh	
Aggregated information	
d) Aggregated volume 16 Ordinary Shares	
Price £15.2440	
e) Date of the transaction 2019-01-10	
f) Place of the transaction London Stock Exchange	(XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name Mr R G Connor	

a) manie	1011	K U COIIIOI
b) Position/status	Pre	esident, Global Vaccines
a) Initial matification		(1.1

- c) Initial notification/amendment Initial notification
 Details of the issuer, emission allowance market participant, auction
- 2. platform, auctioneer or auction monitor
- a) Name
 b) LEI
 b) teails of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)Aggregated information	Price(s)Volume(s)£15.24408 (partnership shares)£15.24408 (matching shares)
d) Aggregated volume Price	16 Ordinary Shares £15.2440
e) Date of the transactionPlace of the transactionf)	2019-01-10 London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to b	e repeated for (i) each type of
3.	instrument; (ii) each type of transaction; where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
		ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c)	Price(s) and volume(s)	Price(s)Volume(s)£15.24408 (partnership shares)£15.24408 (matching shares)
	Aggregated information	
d)	Aggregated volume Price	16 Ordinary Shares £15.2440
e)	Date of the transaction	2019-01-10

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

f)	Place of the transaction	London Stock Exchange (XLON)
 c) 2. a) b) 	Details of PDMR/person closely associa Name Position/status Initial notification/amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; where transaction(s) has been conducted	Mr N Hirons SVP, Global Ethics & Compliance Initial notification market participant, auction GlaxoSmithKline plc 5493000HZTVUYLO1D793 re repeated for (i) each type of (iii) each date; and (iv) each place
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
,	Nature of the transaction Price(s) and volume(s)	Acquisition of Ordinary Shares under the Company's Share Reward Plan. Price(s) Volume(s) £15.2440 8 (partnership shares)
	Aggregated information	£15.2440 8 (matching shares)
d)	Aggregated volume Price	16 Ordinary Shares £15.2440
e)	Date of the transaction	2019-01-10
f)	Place of the transaction	London Stock Exchange (XLON)
b) c) 2.	Details of PDMR/person closely associa Name Position/status Initial notification/amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor	Mr L Miels President, Global Pharmaceuticals Initial notification market participant, auction
	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793
0)	Details of the transaction(s): section to b	

- instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share
c)	Price(s) and volume(s)	Reward Plan. Price(s) Volume(s) £15.2440 8 (partnership shares) £15.2440 8 (matching shares)
	Aggregated information	
d)	Aggregated volume Price	16 Ordinary Shares £15.2440
e)	Date of the transaction	2019-01-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associa	ated with them $('PCA')$
a)	Name	Mr D S Redfern
	Position/status	Chief Strategy Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to b	be repeated for (i) each type of
3.	instrument; (ii) each type of transaction;	(iii) each date; and (iv) each place
	where transaction(s) has been conducted	1
		Ordinary shares of 25 pence each ('Ordinary Shares')
a)	Description of the financial instrument	
	•	ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c)	Price(s) and volume(s)	Price(s)Volume(s)£15.24408 (partnership shares)£15.24408 (matching shares)
	Aggregated information	
d)	Aggregated volume Price	16 Ordinary Shares £15.2440
e)	Date of the transaction	2019-01-10
,	Place of the transaction	Landar Ctarl Frateries (VLON)
f)		London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA') Mr R Simard

a) Name

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

b)	Position/status	President, Pharma Supply Chain	
c)	Initial notification/amendment	Initial notification	
2	Details of the issuer, emission allowance	market participant, auction	
² . platform, auctioneer or auction monito			
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to b	e repeated for (i) each type of	
3.	instrument; (ii) each type of transaction;	(iii) each date; and (iv) each	
	place where transaction(s) has been conducted		
		Ordinary shares of 25 pence	
		each ('Ordinary Shares')	
a)	Description of the financial instrument		
	-	ISIN: GB0009252882	

b) Nature of the transaction